Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 330

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Development of Immunotherapy Combination Strategies in Cancer

Open access
Yap, Timothy A., Parkes, Eileen E., Peng, Weiyi, Moyers, Justin T., Curran, Michael A., Tawbi, Hussein A.·2021·Cancer Discovery

Abstract

Harnessing the immune system to treat cancer through inhibitors of CTLA4 and PD-L1 has revolutionized the landscape of cancer. Rational combination strategies aim to enhance the antitumor effects of immunotherapies, but require a deep understanding of the mechanistic underpinnings of the immune system and robust preclinical and clinical drug development strategies. We review the current approved immunotherapy combinations, before discussing promising combinatorial approaches in clinical trials and detailing innovative preclinical model systems being used to develop rational combinations. We also discuss the promise of high-order immunotherapy combinations, as well as novel biomarker and combinatorial trial strategies.Significance: Although immune-checkpoint inhibitors are approved as dual checkpoint strategies, and in combination with cytotoxic chemotherapy and angiogenesis inhibitors for multiple cancers, patient benefit remains limited. Innovative approaches are required to guide the development of novel immunotherapy combinations, ranging from improvements in preclinical tumor model systems to biomarker-driven trial strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-1209

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Research works printed but not linked: 193

  1. Sharma, 2015, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential, Cell, 161, 205, 10.1016/j.cell.2015.03.030 · DOI · Paper page
  2. Cristescu, 2018, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy, Science, 362, eaar3593, 10.1126/science.aar3593 · DOI · Paper page
  3. Ascierto, 2017, Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 18, 611, 10.1016/S1470-2045(17)30231-0 · DOI · Paper page
  4. Lebbe, 2019, Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial, J Clin Oncol, 37, 867, 10.1200/JCO.18.01998 · DOI · Paper page
  5. Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017 · DOI · Paper page
  6. Lenz, 2020, Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update, J Clin Oncol, 38
  7. Motzer, 2019, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial, Lancet Oncol, 20, 1370, 10.1016/S1470-2045(19)30413-9 · DOI · Paper page
  8. Lebbé, 2018, LBA47: initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511), Ann Oncol, 29, viii737, 10.1093/annonc/mdy424.057 · DOI
  9. He, 2020, Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): subgroup analyses from CheckMate 040, J Clin Oncol, 38, 512, 10.1200/JCO.2020.38.4_suppl.512 · DOI
  10. Yau, 2019, Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040, J Clin Oncol, 37, 4012, 10.1200/JCO.2019.37.15_suppl.4012 · DOI · Paper page
  11. Gadgeel, 2020, Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer, J Clin Oncol, 38, 1505, 10.1200/JCO.19.03136 · DOI · Paper page
  12. Paz-Ares, 2020, A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous non-small-cell lung cancer: protocol-specified final analysis of KEYNOTE-407, J Thorac Oncol, 15, 1657, 10.1016/j.jtho.2020.06.015 · DOI · Paper page
  13. Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697 · DOI · Paper page
  14. Gray, 2020, Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC, J Thorac Oncol, 15, 288, 10.1016/j.jtho.2019.10.002 · DOI · Paper page
  15. Gadgeel, 2018, Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC), J Thorac Oncol, 13, 1393, 10.1016/j.jtho.2018.05.002 · DOI · Paper page
  16. Reck, 2016, Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer, J Clin Oncol, 34, 3740, 10.1200/JCO.2016.67.6601 · DOI · Paper page
  17. Horn, 2018, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer, N Engl J Med, 379, 2220, 10.1056/NEJMoa1809064 · DOI · Paper page
  18. Reck, 2019, IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC), Ann Oncol, 30, v710, 10.1093/annonc/mdz264 · DOI
  19. Denkert, 2015, Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers, J Clin Oncol, 33, 983, 10.1200/JCO.2014.58.1967 · DOI · Paper page
  20. Loi, 2014, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, 25, 1544, 10.1093/annonc/mdu112 · DOI · Paper page
  21. Le, 2020, Evolving role of immunotherapy in recurrent metastatic head and neck cancer, J Natl Compr Canc Netw, 18, 899, 10.6004/jnccn.2020.7590 · DOI
  22. Chow, 2020, Head and neck cancer, N Engl J Med, 382, 60, 10.1056/NEJMra1715715 · DOI · Paper page
  23. Makker, 2020, Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer, J Clin Oncol, 38, 2981, 10.1200/JCO.19.02627 · DOI · Paper page
  24. Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin Cancer Res, 22, 4585, 10.1158/1078-0432.CCR-15-3101 · DOI · Paper page
  25. Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X · DOI · Paper page
  26. Choueiri, 2017, Systemic therapy for metastatic renal-cell carcinoma, N Engl J Med, 376, 354, 10.1056/NEJMra1601333 · DOI · Paper page
  27. Rini, 2019, Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial, Lancet, 393, 2404, 10.1016/S0140-6736(19)30723-8 · DOI · Paper page
  28. Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 · DOI · Paper page
  29. Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745 · DOI · Paper page
  30. Taylor, 2018, A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck [abstract], J Clin Oncol, 36, 6016, 10.1200/JCO.2018.36.15_suppl.6016 · DOI
  31. Dummer, 2020, Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma, N Engl J Med, 383, 1139, 10.1056/NEJMoa2005493 · DOI · Paper page
  32. Dummer, 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 19, 603, 10.1016/S1470-2045(18)30142-6 · DOI · Paper page
  33. Nathan, 2020, LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: results from the randomized part 3 of the phase III COMBI-i trial, Ann Oncol, 31, S1172, 10.1016/j.annonc.2020.08.2273 · DOI
  34. Melero, 2015, Evolving synergistic combinations of targeted immunotherapies to combat cancer, Nat Rev Cancer, 15, 457, 10.1038/nrc3973 · DOI · Paper page
  35. Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2 · DOI · Paper page
  36. De Sousa Linhares, 2019, Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling, Sci Rep, 9, 11472, 10.1038/s41598-019-47910-1 · DOI · Paper page
  37. Deng, 2016, Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor, MAbs, 8, 593, 10.1080/19420862.2015.1136043 · DOI · Paper page
  38. Duan, 2020, Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis, JAMA Oncol, 6, 375, 10.1001/jamaoncol.2019.5367 · DOI · Paper page
  39. Miyashita, 2020, Incidence and risk of colitis with programmed death 1 versus programmed death ligand 1 inhibitors for the treatment of cancer, J Immunother, 43, 291, 10.1097/CJI.0000000000000339 · DOI
  40. Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A, 107, 4275, 10.1073/pnas.0915174107 · DOI · Paper page
  41. Duraiswamy, 2013, Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors, Cancer Res, 73, 3591, 10.1158/0008-5472.CAN-12-4100 · DOI · Paper page
  42. Chung, 2009, Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells, Blood, 114, 555, 10.1182/blood-2008-11-191197 · DOI · Paper page
  43. Munn, 1999, Inhibition of T cell proliferation by macrophage tryptophan catabolism, J Exp Med, 189, 1363, 10.1084/jem.189.9.1363 · DOI · Paper page
  44. Holmgaard, 2013, Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4, J Exp Med, 210, 1389, 10.1084/jem.20130066 · DOI · Paper page
  45. Liu, 2018, Targeting the IDO1 pathway in cancer: from bench to bedside, J Hematol Oncol, 11, 100, 10.1186/s13045-018-0644-y · DOI · Paper page
  46. Prendergast, 2017, Discovery of IDO1 inhibitors: from bench to bedside, Cancer Res, 77, 6795, 10.1158/0008-5472.CAN-17-2285 · DOI · Paper page
  47. Labadie, 2019, Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis, Clin Cancer Res, 25, 1462, 10.1158/1078-0432.CCR-18-2882 · DOI · Paper page
  48. Blackburn, 2009, Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nat Immunol, 10, 29, 10.1038/ni.1679 · DOI · Paper page
  49. Oweida, 2018, Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration, Clin Cancer Res, 24, 5368, 10.1158/1078-0432.CCR-18-1038 · DOI · Paper page
  50. Shayan, 2017, Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer, Oncoimmunology, 6, e1261779, 10.1080/2162402X.2016.1261779 · DOI · Paper page
  51. Davar D, 2018, A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma, J Immunother Cancer, 6, O21
  52. Harding, 2019, A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic findings in advanced cancers, J Clin Oncol, 37, 12, 10.1200/JCO.2019.37.8_suppl.12 · DOI
  53. Durham, 2014, Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo, PLoS One, 9, e109080, 10.1371/journal.pone.0109080 · DOI · Paper page
  54. Huang, 2004, Role of LAG-3 in regulatory T cells, Immunity, 21, 503, 10.1016/j.immuni.2004.08.010 · DOI · Paper page
  55. Workman, 2005, Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223), J Immunol, 174, 688, 10.4049/jimmunol.174.2.688 · DOI · Paper page
  56. Goding, 2013, Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma, J Immunol, 190, 4899, 10.4049/jimmunol.1300271 · DOI · Paper page
  57. Wierz, 2018, Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia, Blood, 131, 1617, 10.1182/blood-2017-06-792267 · DOI
  58. Hong, 2018, Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies, J Clin Oncol, 36, 3012, 10.1200/JCO.2018.36.15_suppl.3012 · DOI
  59. Ascierto, 2017, Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations, Ann Oncol, 28, v611, 10.1093/annonc/mdx440.011 · DOI
  60. Lakhani N, 2018, The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study, J Immunother cancer, O114
  61. Weber, 2018, 1304TiP - A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM), Ann Oncol, 29, viii465, 10.1093/annonc/mdy289.060 · doi:10.1093/annonc/mdy289.060
  62. Yu, 2017, Recent advances of bispecific antibodies in solid tumors, J Hematol Oncol, 10, 155, 10.1186/s13045-017-0522-z · DOI
  63. Hickingbottom, 2020, Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors, J Clin Oncol, 38, e15001, 10.1200/JCO.2020.38.15_suppl.e15001 · doi:10.1200/jco.2020.38.15_suppl.e15001
  64. Hou, 2019, A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer, Invest New Drugs, 37, 876, 10.1007/s10637-018-0689-3 · DOI
  65. Li, 2020, Cancer immunotherapy via targeted TGF-β signalling blockade in T(H) cells, Nature, 587, 121, 10.1038/s41586-020-2850-3 · DOI · Paper page
  66. Blank, 2018, Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma, Nat Med, 24, 1655, 10.1038/s41591-018-0198-0 · DOI · Paper page
  67. Chen, 2018, Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response, Nature, 560, 382, 10.1038/s41586-018-0392-8 · DOI · Paper page
  68. Chalabi, 2020, Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers, Nat Med, 26, 566, 10.1038/s41591-020-0805-8 · DOI · Paper page
  69. Schoenfeld, 2020, Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial, JAMA Oncol, 6, 1563, 10.1001/jamaoncol.2020.2955 · DOI · Paper page
  70. Caudana, 2019, IL2/anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation, Cancer Immunol Res, 7, 443, 10.1158/2326-6066.CIR-18-0697 · DOI
  71. Cho, 2007, An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2, J Exp Med, 204, 1787, 10.1084/jem.20070740 · DOI
  72. Langowski, 2016, Abstract B057: the CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity, Cancer Immunol Res, 4, B057, 10.1158/2326-6066.IMM2016-B057 · doi:10.1158/2326-6066.imm2016-b057
  73. Diab, 2020, Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02), Cancer Discov, 10, 1158, 10.1158/2159-8290.CD-19-1510 · DOI · Paper page
  74. Curti, 2013, OX40 is a potent immune-stimulating target in late-stage cancer patients, Cancer Res, 73, 7189, 10.1158/0008-5472.CAN-12-4174 · DOI · Paper page
  75. Goodwin, 1993, Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor, Eur J Immunol, 23, 2631, 10.1002/eji.1830231037 · DOI · Paper page
  76. Zappasodi, 2019, Abstract PR01: mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients, Cancer Immunol Res, 7, PR01, 10.1158/2326-6074.CRICIMTEATIAACR18-PR01 · doi:10.1158/2326-6074.cricimteatiaacr18-pr01
  77. Ribas, 2018, SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study, Cancer Discov, 8, 1250, 10.1158/2159-8290.CD-18-0280 · DOI · Paper page
  78. Reilley, 2019, Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors, J Clin Oncol, 37, TPS2669, 10.1200/JCO.2019.37.15_suppl.TPS2669 · doi:10.1200/jco.2019.37.15_suppl.tps2669
  79. Diab, 2018, 1245PD – Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): results from a multicenter, phase I/II study, Ann Oncol, 29, viii442, 10.1093/annonc/mdy289.001 · doi:10.1093/annonc/mdy289.001
  80. Butler, 2019, ILLUMINATE 301: a randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy, J Clin Oncol, 37, TPS9599, 10.1200/JCO.2019.37.15_suppl.TPS9599 · DOI
  81. Curran, 2012, Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions, J Gene Med, 14, 405, 10.1002/jgm.2604 · DOI · Paper page
  82. Adusumilli, 2019, Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent, J Clin Oncol, 37, 2511, 10.1200/JCO.2019.37.15_suppl.2511 · DOI
  83. Grosser, 2019, Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors, Cancer Cell, 36, 471, 10.1016/j.ccell.2019.09.006 · DOI · Paper page
  84. Schwartz, 1973, Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression, Cancer Res, 33, 1837
  85. Pfirschke, 2016, Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy, Immunity, 44, 343, 10.1016/j.immuni.2015.11.024 · DOI · Paper page
  86. Heinhuis, 2019, Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors, Ann Oncol, 30, 219, 10.1093/annonc/mdy551 · DOI · Paper page
  87. Erdal, 2017, A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1, Genes Dev, 31, 353, 10.1101/gad.289769.116 · DOI · Paper page
  88. Fu, 2015, STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade, Sci Transl Med, 7, 283ra52, 10.1126/scitranslmed.aaa4306 · DOI · Paper page
  89. Kodumudi, 2012, Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma, J Immunol, 189, 5147, 10.4049/jimmunol.1200274 · DOI
  90. Ma, 2013, Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells, Immunity, 38, 729, 10.1016/j.immuni.2013.03.003 · DOI · Paper page
  91. Nanda, 2017, Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2, J Clin Oncol, 35, 506, 10.1200/JCO.2017.35.15_suppl.506 · DOI · Paper page
  92. Deng, 2014, STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors, Immunity, 41, 843, 10.1016/j.immuni.2014.10.019 · DOI · Paper page
  93. Sato, 2017, DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells, Nat Commun, 8, 1751, 10.1038/s41467-017-01883-9 · DOI · Paper page
  94. Shevtsov, 2019, Novel approaches to improve the efficacy of immuno-radiotherapy, Front Oncol, 9, 156, 10.3389/fonc.2019.00156 · DOI · Paper page
  95. Ko, 2018, The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer, Clin Cancer Res, 24, 5792, 10.1158/1078-0432.CCR-17-3620 · DOI · Paper page
  96. Komatsu, 2017, Abscopal effect of nivolumab in a patient with primary lung cancer, J Thorac Oncol, 12, e143, 10.1016/j.jtho.2017.05.004 · doi:10.1016/j.jtho.2017.05.004
  97. Yuan, 2017, Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1-negative metastatic squamous cell carcinoma of the lung, J Thorac Oncol, 12, e135, 10.1016/j.jtho.2017.04.029 · DOI
  98. Gratia, 2019, Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS, J Exp Med, 216, 1199, 10.1084/jem.20181329 · DOI
  99. Shen, 2019, PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness, Cancer Res, 79, 311, 10.1158/0008-5472.CAN-18-1003 · DOI · Paper page
  100. Ding, 2019, PARP1 suppresses the transcription of PD-L1 by poly(ADP-Ribosyl)ating STAT3, Cancer Immunol Res, 7, 136, 10.1158/2326-6066.CIR-18-0071 · DOI
  101. Karzai, 2018, Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations, J Immunother Cancer, 6, 141, 10.1186/s40425-018-0463-2 · DOI · Paper page
  102. Yu, 2019, Keynote-365 cohort A: pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC), J Clin Oncol, 37, 145, 10.1200/JCO.2019.37.7_suppl.145 · DOI
  103. Konstantinopoulos, 2018, TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort, J Clin Oncol, 36, 106, 10.1200/JCO.2018.36.15_suppl.106 · DOI
  104. Yap, 2016, Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers, Eur J Cancer, 69, S2, 10.1016/S0959-8049(16)32607-7 · DOI
  105. Friedman, 2018, Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies, J Immunother Cancer, 6, 59, 10.1186/s40425-018-0374-2 · DOI
  106. Jin, 2020, Therapeutic co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer, Cancer Res Treat, 52, 149, 10.4143/crt.2019.183 · DOI
  107. Zhang, 2018, ATMJAKPDL1 signaling pathway inhibition decreases EMT and metastasis of androgenindependent prostate cancer, Mol Med Rep, 17, 7045
  108. Tsai, 2017, A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies, Cancer Immunol Res, 5, 790, 10.1158/2326-6066.CIR-17-0009 · DOI
  109. Brea, 2016, Kinase regulation of human MHC class I molecule expression on cancer cells, Cancer Immunol Res, 4, 936, 10.1158/2326-6066.CIR-16-0177 · DOI · Paper page
  110. Ribas, 2013, Hepatotoxicity with combination of vemurafenib and ipilimumab, N Engl J Med, 368, 1365, 10.1056/NEJMc1302338 · DOI · Paper page
  111. Minor, 2015, Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab, Pigment Cell Melanoma Res, 28, 611, 10.1111/pcmr.12383 · DOI
  112. Ascierto, 2018, 1244O - KEYNOTE-022 Part 3: phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma, Ann Oncol, 29, viii442, 10.1093/annonc/mdy289 · DOI
  113. Bendell, 2018, LBA-004: efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer, Ann Oncol, 29, v123, 10.1093/annonc/mdy208.003 · DOI
  114. Orillion, 2017, Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma, Clin Cancer Res, 23, 5187, 10.1158/1078-0432.CCR-17-0741 · DOI · Paper page
  115. Zheng, 2016, HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma, Clin Cancer Res, 22, 4119, 10.1158/1078-0432.CCR-15-2584 · DOI · Paper page
  116. Sullivan, 2019, Abstract CT072: efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy, Cancer Res, 79, CT072, 10.1158/1538-7445.AM2019-CT072 · DOI
  117. Ørskov, 2017, Activation of T cells specific to endogenous retroviral peptides: possible association with clinical response to azacitidine in myeloid malignancies, Blood, 130, 4243
  118. Daver, 2019, Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study, Cancer Discov, 9, 370, 10.1158/2159-8290.CD-18-0774 · DOI · Paper page
  119. Lee, 2017, Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer, J Clin Oncol, 35, 3054, 10.1200/JCO.2017.35.15_suppl.3054 · DOI
  120. Alvarez, 2011, B16 murine melanoma: historical perspective on the development of a solid tumor model, 79, 10.1007/978-1-60761-968-0_4 · doi:10.1007/978-1-60761-968-0_4
  121. Barth, 1990, Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes, J Immunol, 144, 1531, 10.4049/jimmunol.144.4.1531 · DOI
  122. Kim, 1979, Establishment and characterization of BALB/c lymphoma lines with B cell properties, J Immunol, 122, 549, 10.4049/jimmunol.122.2.549 · DOI · Paper page
  123. Gajewski, 2001, The p815 mastocytoma tumor model, Curr Protoc Immunol, 10.1002/0471142735.im2004s43 · doi:10.1002/0471142735.im2004s43
  124. Aslakson, 1992, Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor, Cancer Res, 52, 1399
  125. Summerhayes, 1979, Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro, J Natl Cancer Inst, 62, 1017
  126. Corbett, 1975, Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure, Cancer Res, 35, 2434
  127. Wang, 1995, Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen, J Immunol, 154, 4685, 10.4049/jimmunol.154.9.4685 · DOI · Paper page
  128. Castle, 2012, Exploiting the mutanome for tumor vaccination, Cancer Res, 72, 1081, 10.1158/0008-5472.CAN-11-3722 · DOI · Paper page
  129. Krupke, 2017, The mouse tumor biology database: a comprehensive resource for mouse models of human cancer, Cancer Res, 77, e67, 10.1158/0008-5472.CAN-17-0584 · DOI
  130. Dankort, 2009, Braf(V600E) cooperates with Pten loss to induce metastatic melanoma, Nat Genet, 41, 544, 10.1038/ng.356 · DOI · Paper page
  131. Hooijkaas, 2012, Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma, Oncoimmunology, 1, 609, 10.4161/onci.20226 · DOI
  132. Kimpfler, 2009, Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs, J Immunol, 183, 6330, 10.4049/jimmunol.0900609 · DOI
  133. Le, 1989, Cytotoxic T cell responses in HLA-A2.1 transgenic mice: recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element, J Immunol, 142, 1366, 10.4049/jimmunol.142.4.1366 · DOI
  134. Lute, 2005, Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies, Blood, 106, 3127, 10.1182/blood-2005-06-2298 · DOI
  135. Huang, 2018, Abstract A207: utilizing human OX40 knock-in mice (HuGEMMTM) to assess antitumor efficacy of OX40-agonistic antibodies, Mol Cancer Ther, 17, A207, 10.1158/1535-7163.TARG-17-A207 · doi:10.1158/1535-7163.targ-17-a207
  136. Zheng, 2018, Abstract A203: generation of human TIM3 knock-in mice for preclinical efficacy assessment of therapeutic antibodies, Mol Cancer Ther, 17, A203, 10.1158/1535-7163.TARG-17-A203 · doi:10.1158/1535-7163.targ-17-a203
  137. Jangalwe, 2016, Improved B cell development in humanized NOD-scid IL2Rgamma(null) mice transgenically expressing human stem cell factor, granulocyte-macrophage colony-stimulating factor and interleukin-3, Immun Inflamm Dis, 4, 427, 10.1002/iid3.124 · DOI
  138. Saito, 2016, Peripheral blood CD34(+) cells efficiently engraft human cytokine knock-in mice, Blood, 128, 1829, 10.1182/blood-2015-10-676452 · DOI
  139. Wang, 2018, Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy, FASEB J, 32, 1537, 10.1096/fj.201700740R · DOI · Paper page
  140. Capasso, 2019, Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts, J Immunother Cancer, 7, 37, 10.1186/s40425-019-0518-z · DOI · Paper page
  141. Beatty, 2011, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331, 1612, 10.1126/science.1198443 · DOI · Paper page
  142. O'Hara, 2019, Abstract CT004: a phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients, Cancer Res, 79, CT004, 10.1158/1538-7445.AM2019-CT004 · DOI
  143. Desnoyers, 2013, Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index, Sci Transl Med, 5, 207ra144, 10.1126/scitranslmed.3006682 · DOI · Paper page
  144. Naing, 2019, CX-072, a PD-L1 probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072, J Clin Oncol, 37, 2513, 10.1200/JCO.2019.37.15_suppl.2513 · DOI
  145. Hinner, 2019, Tumor-localized costimulatory T-cell engagement by the 4-1BB/HER2 bispecific antibody-anticalin fusion PRS-343, Clin Cancer Res, 25, 5878, 10.1158/1078-0432.CCR-18-3654 · DOI
  146. Aznar, 2017, Intratumoral delivery of immunotherapy-act locally, think globally, J Immunol, 198, 31, 10.4049/jimmunol.1601145 · DOI · Paper page
  147. Sagiv-Barfi, 2018, Eradication of spontaneous malignancy by local immunotherapy, Sci Transl Med, 10, eaan4488, 10.1126/scitranslmed.aan4488 · DOI · Paper page
  148. Ager, 2017, Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity, Cancer Immunol Res, 5, 676, 10.1158/2326-6066.CIR-17-0049 · DOI · Paper page
  149. Leone, 2018, Targeting adenosine for cancer immunotherapy, J Immunother Cancer, 6, 57, 10.1186/s40425-018-0360-8 · DOI · Paper page
  150. Park, 2012, Istradefylline for the treatment of Parkinson's disease, Expert Opin Pharmacother, 13, 111, 10.1517/14656566.2012.643869 · DOI
  151. Congreve, 2018, Targeting adenosine A2A receptor antagonism for treatment of cancer, Expert Opin Drug Discov, 13, 997, 10.1080/17460441.2018.1534825 · DOI
  152. Pinter, 2017, Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy, Sci Transl Med, 9, eaan5616, 10.1126/scitranslmed.aan5616 · DOI · Paper page
  153. Rachidi, 2017, Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis, Sci Immunol, 2, eaai7911, 10.1126/sciimmunol.aai7911 · DOI · Paper page
  154. Serafini, 2006, Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function, J Exp Med, 203, 2691, 10.1084/jem.20061104 · DOI · Paper page
  155. Kluger, 2020, Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce, J Immunother Cancer, 8, e000398, 10.1136/jitc-2019-000398 · DOI · Paper page
  156. Schvartsman, 2019, Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma, Cancer, 125, 4193, 10.1002/cncr.32454 · DOI
  157. Food and Drug Administration H, 2020, Cancer clinical trial eligibility criteria: brain metastases guidance for industry, Fed Regist, 85, 41992
  158. Gibney, 2019, Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma, J Immunother Cancer, 7, 80, 10.1186/s40425-019-0562-8 · DOI
  159. Daver, 2018, Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes, Leukemia, 32, 1094, 10.1038/s41375-018-0070-8 · DOI · Paper page
  160. Wang, 2019, Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas, Cancer Immunol Res, 7, 1318, 10.1158/2326-6066.CIR-18-0875 · DOI
  161. Mao, 2019, Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition, J Immunother Cancer, 7, 277, 10.1186/s40425-019-0758-y · DOI
  162. Lemery, 2017, First FDA approval agnostic of cancer site — when a biomarker defines the indication, N Engl J Med, 377, 1409, 10.1056/NEJMp1709968 · DOI · Paper page
  163. Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J Clin Oncol, 38, 1, 10.1200/JCO.19.02105 · DOI · Paper page
  164. Hierro, 2019, Agnostic-histology approval of new drugs in oncology: are we already there?, Clin Cancer Res, 25, 3210, 10.1158/1078-0432.CCR-18-3694 · DOI
  165. Gandara, 2018, Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, 24, 1441, 10.1038/s41591-018-0134-3 · DOI · Paper page
  166. Osipov, 2020, Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis, Clin Cancer Res, 26, 4842, 10.1158/1078-0432.CCR-20-0458 · DOI
  167. Pitt, 2016, Fine-tuning cancer immunotherapy: optimizing the gut microbiome, Cancer Res, 76, 4602, 10.1158/0008-5472.CAN-16-0448 · DOI
  168. Davar, 2019, Abstract IA38: manipulating the gut microbiome to improve immunotherapy of melanoma, Cancer Immunol Res, 7, IA38, 10.1158/2326-6074.CRICIMTEATIAACR18-IA38 · DOI
  169. Reck, 2020, Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA, J Clin Oncol, 38, 9501, 10.1200/JCO.2020.38.15_suppl.9501 · DOI · Paper page
  170. Reck, 2019, Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial, Lancet Respir Med, 7, 387, 10.1016/S2213-2600(19)30084-0 · DOI · Paper page
  171. Plimack, 2020, Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): updated analysis of KEYNOTE-426, J Clin Oncol, 38, 5001, 10.1200/JCO.2020.38.15_suppl.5001 · DOI
  172. Choueiri, 2020, Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma, Ann Oncol, 31, 1030, 10.1016/j.annonc.2020.04.010 · DOI · Paper page
  173. Grasselly, 2018, The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent, Front Immunol, 9, 2100, 10.3389/fimmu.2018.02100 · DOI
  174. Tallon de Lara, 2018, Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients, Clin Cancer Res, 24, 6345, 10.1158/1078-0432.CCR-18-1231 · DOI
  175. Burlion, 2019, A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system, Oncoimmunology, 8, 1596005, 10.1080/2162402X.2019.1596005 · DOI
  176. Wang, 2015, Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model, Cancer Immunol Res, 3, 1030, 10.1158/2326-6066.CIR-15-0073 · DOI · Paper page
  177. Stone, 2017, Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden, Proc Natl Acad Sci U S A, 114, E10981, 10.1073/pnas.1712514114 · DOI · Paper page
  178. Rojas, 2015, Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy, Clin Cancer Res, 21, 5543, 10.1158/1078-0432.CCR-14-2009 · DOI
  179. Saha, 2017, Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade, Cancer Cell, 32, 253, 10.1016/j.ccell.2017.07.006 · DOI · Paper page
  180. Bourgeois-Daigneault, 2018, Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy, Sci Transl Med, 10, eaao1641, 10.1126/scitranslmed.aao1641 · DOI · Paper page
  181. Speranza, 2018, Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma, Neuro Oncol, 20, 225, 10.1093/neuonc/nox139 · DOI
  182. Verbrugge, 2012, Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies, Cancer Res, 72, 3163, 10.1158/0008-5472.CAN-12-0210 · DOI · Paper page
  183. Kroon, 2016, Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma, Cancer Immunol Immunother, 65, 753, 10.1007/s00262-016-1843-4 · DOI
  184. Zhao, 2019, Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer, Nat Commun, 10, 899, 10.1038/s41467-019-08782-1 · DOI · Paper page
  185. Moon, 2016, Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer, Clin Cancer Res, 22, 436, 10.1158/1078-0432.CCR-15-1070 · DOI
  186. Garton, 2017, Anti-KIT monoclonal antibody treatment enhances the antitumor activity of immune checkpoint inhibitors by reversing tumor-induced immunosuppression, Mol Cancer Ther, 16, 671, 10.1158/1535-7163.MCT-16-0676 · DOI · Paper page
  187. De Henau, 2016, Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells, Nature, 539, 443, 10.1038/nature20554 · DOI · Paper page
  188. Kaneda, 2016, PI3Kγ is a molecular switch that controls immune suppression, Nature, 539, 437, 10.1038/nature19834 · DOI · Paper page
  189. Homet Moreno, 2016, Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma, OncoImmunology, 5, e1052212, 10.1080/2162402X.2015.1052212 · DOI
  190. Sai, 2017, PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses, Clin Cancer Res, 23, 3371, 10.1158/1078-0432.CCR-16-2142 · DOI · Paper page
  191. Kim, 2019, The COX2 effector microsomal PGE2 synthase 1 is a regulator of immunosuppression in cutaneous melanoma, Clin Cancer Res, 25, 1650, 10.1158/1078-0432.CCR-18-1163 · DOI
  192. Kinkead, 2018, Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer, JCI Insight, 3, e122857, 10.1172/jci.insight.122857 · DOI · Paper page
  193. Zaidi, 2019, Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL3-dependent CD4(+) effector T cell infiltration into murine pancreatic tumors, Ann N Y Acad Sci, 1445, 62, 10.1111/nyas.14049 · DOI

Cited by

See all 330

Metadata

Authors
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A.
Venue
Cancer Discovery
Published
2021-04-02
Volume
11
Issue
6
Pages
1368-1397
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3141168022
Cited by
330
References
75
FWCI
17.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of Immunotherapy Combination Strategies in Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-1209
The paper
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021). Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-1209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.